Enhanced Cytotoxicity of Rituximab Following Genetic and Biochemical Disruption of Glycosylphosphatidylinositol Anchored Proteins

References

• Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., et al. (1997) "IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma". Journal of Clinical Oncology, 15, 3266–3274.
   PubMed Web of Science ®Google Scholar
• Maloney, D.G., Grillo-Lopez, A.J., White, CA., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. (1997) "IDEC-C2B8 (Ritux-imab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma". Blood, 90, 2188–2195.
   PubMed Web of Science ®Google Scholar
• Levine, T.D. and Pestronk, A. (1999) "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituxi-mab". Neurology, 52, 1701–1704.
   Google Scholar
• Stasi, R., Pagano, A., Stipa, E. and Amadori, S. (2001) "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura". Blood, 98, 952–957.
   PubMed Web of Science ®Google Scholar
• Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., et al. (2000) "European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and pre-viously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma". Journal of Clinical Oncology, 18, 317–324.
   PubMed Web of Science ®Google Scholar
• Scallon, B.J., Moore, M.A., Trinh, H., Knight, D.M. and Ghrayeb, J. (1995) "Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions". Cytokine, 7, 251–259.
   PubMed Web of Science ®Google Scholar
• Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., et al. (2000) "Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis". Blood, 95, 3900–3908.
   PubMed Web of Science ®Google Scholar
• Harjunpaa, A., Junnikkala, S. and Men, S. (2000) "Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms". Scandinavian Journal of Immunology, 51, 634–641.
   Google Scholar
• Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., et al. (2001) "Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies". Journal of Immunotherapy, 24, 263–271.
   PubMed Web of Science ®Google Scholar
• Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., et al. (2001) "CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59". Blood, 98, 3383 — 3389.
   PubMed Web of Science ®Google Scholar
• Miyata, T., Takeda, J., Iida, Y., Yamada, N., Inoue, N., Takahashi, M., et al. (1993) "The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis". Science, 259, 1318 — 1320.
   PubMed Web of Science ®Google Scholar
• Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., et al. (1993) "Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobi-nuria". Cell, 73, 703–711.
   PubMed Web of Science ®Google Scholar
• Miyata, T., Yamada, N., Iida, Y., Nishimura, J., Takeda, J., Kitani, T., et al. (1994) "Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglo-binuria". New England Journal of Medicine, 330, 249–255.
   PubMed Web of Science ®Google Scholar
• Bessler, M., Mason, P.J., Hillmen, P., Miyata, T., Yamada, N., Takeda, J., et al. (1994) "Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene". The EMBO Journal, 13, 110–117.
   PubMed Web of Science ®Google Scholar
• Nagarajan, S., Brodsky, R.A., Young, N.S. and Medof, M.E. (1995) "Genetic defects underlying paroxysmal nocturnal hemo-globinuria that arises out of aplastic anemia". Blood, 86, 4656 — 4661.
   PubMed Web of Science ®Google Scholar
• Rosse, W.F. and Ware, R.E. (1995) "The molecular basis of paroxysmal nocturnal hemoglobinuria". Blood, 86, 3277–3286.
   PubMed Web of Science ®Google Scholar
• Rosse, W.F. (1997) "Paroxysmal nocturnal hemoglobinuria as a molecular disease". Medicine, 76, 63–93.
   PubMed Web of Science ®Google Scholar
• Venneker, G.T., Vodegel, R.M., Okada, N., Westerhof, W., Bos, J,D. and Asghar, S.S. (1998) "Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement". Immunobiology, 198, 476–484.
   PubMed Web of Science ®Google Scholar
• Brodsky, R.A., Vala, M.S., Barber, J.P., Medof, M.E. and Jones, R.J. (1997) "Resistance to Apoptosis Caused by PIG-A Gene Mutations in Paroxymal Nocturnal Hemoglobinuria". Proceedings of the National Academy of Sciences of the United States of America, 94, 8756–8760.
   PubMed Web of Science ®Google Scholar
• Brodsky, R.A., Jane, S.M., Vanin, E.F., Mitsuya, H., Peters, T.R., Shimada, T., et al. (1995) "Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer". Human Gene Therapy, 5, 1231 —1239.
   Web of Science ®Google Scholar
• Treon, S.P., Pilarski, L.M., Belch, AR., Kelliher, A., Preffer, Fl., Shima, Y., et al. (2002) "Anderson, K.C., CD20-directed serotherapy in patients with multiple myeloma: biologic considera-tions and therapeutic applications". Journal of Immunotherapy, 25, 72 — 81.
   PubMed Web of Science ®Google Scholar
• Medof, M.E., Kinoshita, T. and Nussenzweig, V. (1994) "Inhibition of complement activation on the surface of cells after incorpora-tion of decay-accelerating factor (DAF) into their membranes". The Journal of Experimental Medicine, 160, 1558–1578.
   Web of Science ®Google Scholar
• Wilcox, L.A., Ezzell, J.L., Bernshaw, N.J., Parker, C.J. (1991) "Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum". Blood, 78[3], 820–829.
   PubMed Web of Science ®Google Scholar
• Holt, D.S., Botto, M., Bygrave, A.E., Hanna, S.M., Walport, and Morgan, B.P. (2001) "Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria". Blood, 98, 442–449.
   PubMed Web of Science ®Google Scholar
• Derigs, H.G. (2000) "In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs". Cytotherapy, 2, 445–453.
   PubMed Web of Science ®Google Scholar